Code Bio: Code Bio and Takeda collaborate to develop gene therapies for rare diseases
The deal value of the partnership totals to up to $2bn if milestones for all four programmes are met. The post Code Bio and Takeda collaborate to develop gene therapies for rare diseases appeared first on Pharmaceutical Technology.
Read full article »
Code Bio is a Pennsylvania-based biotechnology company that develops and commercializes non-viral gene therapies for the treatment of rare diseases.
Read more